![]() securities laws, including, but not limited to, statements regarding the expected date of trading of the Common Shares on a post-Reverse Stock Split basis, as well as statements relating to the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. This press release contains forward-looking statements within the meaning of Canadian and U.S. For more information, please visit Forward Looking Statements The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML) and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. ![]() The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. No fractional Common Shares will be issued as a result of the Reverse Stock Split and shareholders will not receive any compensation in lieu thereof.Īptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. ![]() The Company’s Board of Directors then approved a ratio of 15-to-1 on May 23, 2023.Īs a result of the Reverse Stock Split, every 15 Common Shares issued and outstanding were automatically reclassified into one new Common Share. The new CUSIP number for the Common Shares is 03835T309 and the new ISIN is CA03835T3091.Īs previously announced, the Reverse Stock Split, at a ratio in the range between 10-to-1 and 20-to-1, was approved at the Company’s annual and special meeting of shareholders held on and is described in the proxy statement dated April 18, 2023. The Common Shares continue to trade on the Nasdaq and the TSX under the existing ticker symbols. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the Company effected a reverse stock split on at a ratio of 15-to-1 (the “Reverse Stock Split”).īoth the Nasdaq Capital Market (“Nasdaq”) and the Toronto Stock Exchange (“TSX”) have approved the Reverse Stock Split and have informed the Company that its common shares (the “Common Shares”) will commence trading on a post-Reverse Stock Split basis at market open on Tuesday, June 6, 2023. ![]() SAN DIEGO and TORONTO, J(GLOBE NEWSWIRE) - Aptose Biosciences Inc. ![]()
0 Comments
Leave a Reply. |